An open-label, randomised, parallel group study to evaluate pharmacokinetics, safety and tolerability of single-dose of Sacubitril/valsartan (LCZ696) in healthy Chinese male volunteers

Trial Profile

An open-label, randomised, parallel group study to evaluate pharmacokinetics, safety and tolerability of single-dose of Sacubitril/valsartan (LCZ696) in healthy Chinese male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 16 Mar 2016 New trial record
    • 09 Mar 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top